Increased Expression of TLR10 in B Cell Subsets Correlates with Disease Activity in Rheumatoid Arthritis
Table 2
TLR10 expression in B cells and B cell subsets in the study subjects.
Control ()
RA ()
LA ()
MA ()
HA ()
#
CD19+
%
51.4 ± 2.4
53.0 ± 1.7
0.612
43.8 ± 2.0
51.9 ± 2.5
60.2 ± 2.9
0.001
MFI
17.5 ± 0.4
17.5 ± 0.3
0.908
16.2 ± 0.2
17.1 ± 0.4
18.7 ± 0.6
0.03
CD19+CD27+
%
73.3 ± 2.2
72.7 ± 1.6
0.829
67.1 ± 3.3
72.2 ± 7.4
76.8 ± 2.6
0.038
MFI
22.7 ± 1.0
22.8 ± 0.6
0.932
20.8 ± 0.7
21.8 ± 0.7
25.1 ± 1.3
0.093
CD19+CD27−
%
43.7 ± 2.4
46.5 ± 1.8
0.385
36.8 ± 2.4
45.2 ± 2.3
54.2 ± 3.2
0.001
MFI
15.4 ± 0.3
15.9 ± 0.2
0.207
20.8 ± 0.7
15.6 ± 0.3
16.9 ± 0.5
≤0.001
CD19+CD27+IgD−
%
78.3 (60.6-83.5)
74.5 (61.5-84.3)
0.914
62.1 (58.6-78.8)
74.8 (62.0-80.8)
80.1 (65.3-87.3)
0.054
FI
22.5 (19.0-25.1)
21.9 (19.5-25.0)
0.819
20.4 (18.4-22.9)
21.7 (19.2-25.2)
22.1 (20.2-31.1)
0.097
CD19+CD27+IgD+
%
72.3 (55.8-81.4)
72.2 (61.0-84.6)
0.479
70.0 (53.9-78.3)
69.4 (57.8-83.5)
77.6 (67.8-88.5)
0.026
FI
18.8 (17.5-22.6)
20.6 (17.9-24.2)
0.276
18.3 (16.4-22.1)
19.8 (18.1-25.8)
21.9 (18.5-26.1)
0.101
CD19+CD27−IgD+
%
43.8 (33.9-55.0)
43.4 (35.1-55.4)
0.737
38.9 (28.2-41.9)
43.5 (37.5-53.1)
54.4 (38.9-68.6)
0.001
FI
15.4 (14.1-16.4)
15.0 (13.9-16.4)
0.605
14.1 (13.8-14.6)
15.5 (14.0-15.9)
15.7 (14.6-18.1)
0.002
CD19+CD27−IgD−
%
40.5 (26.4-49.8)
42.8 (35.0-62.2)
0.047
36.7 (26.1-46.4)
41.6 (33.5-61.8)
54.5 (39.0-67.9)
0.016
MFI
16.7 (15.0-18.3)
17.0 (15.3-20.4)
0.167
16.3 (15.3-17.2)
18.1 (15.1-20.7)
18.3 (15.7-21.7)
0.126
CD19+CD5+
%
34.6 (25.7-46.8)
44.3 (33.2-54.0)
0.024
36.0 (30.5-44.2)
44.3 (32.6-52.8)
52.0 (42.7-68.0)
0.002
MFI
16.1 (14.1-17.0)
16.1 (14.6-17.5)
0.397
14.6 (14.2-16.8)
16.4 (15.2-17.3)
16.5 (15.0-18.6)
0.034
CD19+CD5−
%
52.1 (36.2-63.4)
45.0 (34.9-59.0)
0.435
41.1 (35.0-45.4)
41.9 (30.7-58.2)
51.7 (39.4-67.6)
0.033
MFI
16.9 (15.5-19.0)
16.5 (15.3-18.5)
0.304
15.8 (15.0-17.2)
15.8 (15.0-19.0)
16.8 (15.8-18.9)
0.098
The data are shown as the means ± SE or median (interquartile range, 25th-75th). represents a comparison between the RA subjects and HCs based on the Mann–Whitney test. # represents a comparison among the three groups of RA subjects based on the Kruskal–Wallis test.
